Effects of concomitant inhibition of the PI3K/AKT/mTOR pathway and Bcl-2/Bcl-xL (BCL2L1) were examined in human myeloid leukemia cells. Tetracycline-inducible Bcl-2 and Bcl-xL dual knockdown sharply increased PI3K/AKT/mTOR inhibitor lethality. Conversely, inducible knockdown or dominant-negative AKT increased whereas constitutively active AKT reduced lethality of the Bcl-2/Bcl-xL inhibitor ABT-737. Furthermore, PI3K/mTOR inhibitors (e.g., BEZ235, PI-103) synergistically increased ABT-737-mediated cell death in multiple leukemia cell lines and reduced colony-formation in leukemic but not normal CD34+ cells. on October 3, 2017.
PI3K/mTOR and Bcl-2/Bcl-xL inhibition in leukemia
INTRODUCTION
PI3K/AKT/mTOR is one of the most frequently dysregulated survival signaling pathways in cancer due to multiple genetic aberrations (1) . In acute myelogenous leukemia (AML), this pathway is activated in 50-80% of patients (2) and is frequently associated with FLT3, Ras, and c-KIT mutations (2), PI3K delta isoform amplification (3), or autocrine IGF-1/IGF-1R signaling induction (4) . Activation of PI3K leads to AKT activation, which signals to various downstream substrates including GSK-3, FOXO, mTOR, Bad, MDM2 and NF-țB, and modulates diverse cell processes including survival, proliferation, apoptosis, and autophagy, among others (5) . Recently, multiple inhibitors of this pathway have been developed, several of which (e.g., BEZ235, GDC0981) are currently undergoing clinical evaluation in various tumor types including AML (6).
Over-expression of anti-apoptotic Bcl-2 members such as Bcl-2, Bcl-xL, and Mcl-1, occurs frequently in cancers, particularly hematological malignancies such as AML, resulting in defective apoptosis leading to enhanced cell survival and drug resistance (7). Several agents have been developed to target these proteins directly e.g., ABT-737, a BH3 mimetic that binds PI3K/mTOR and Bcl-2/Bcl-xL inhibition in leukemia PI3K/mTOR and Bcl-2/Bcl-xL inhibition in leukemia
RESULTS
Ectopic expression of Bcl-2 or Bcl-xL increases leukemia cell resistance to apoptosis induced by inhibitors of the PI3K/AKT pathway.
To test the hypothesis that Bcl-2 and Bcl-xL confer resistance to PI3K/AKT pathway inhibition in leukemia cells, U937 cells ectopically overexpressing Bcl-2 or Bcl-xL were employed. These cells displayed significant resistance to the dual PI3K/mTOR inhibitors BEZ235 and PI-103, and the AKT inhibitor perifosine (Supplementary Figure 1A) , as well as the PI3K inhibitor LY294002 (data not shown), raising the possibility that Bcl-2 and Bcl-xL inhibition may potentiate leukemia cell apoptosis induced by PI3K/AKT/mTOR pathway inhibitors.
Dual knockdown of Bcl-2 and Bcl-xL strikingly potentiates PI3K inhibitor-mediated apoptosis in U937 cells.
To determine whether Bcl-2 and Bcl-xL disruption in U937 cells enhances PI3K-mediated apoptosis, inducible knockdown of Bcl-2, Bcl-xL, or both was carried out using a tetinducible shRNA lentiviral system. Time course analysis ( Figure 1A , upper panel) revealed that doxycycline induced a sharp decline in levels of Bcl-2, Bcl-xL, or both in the corresponding cells which was observed after 48 h exposure and persisted over the ensuing 48 h. Interestingly, while individual knockdown of Bcl-2 or Bcl-xL modestly but significantly increased BEZ235, Author Manuscript Published OnlineFirst on December 12, 2012; DOI: 10.1158/0008-5472. CAN-12-1365 PI3K/mTOR and Bcl-2/Bcl-xL inhibition in leukemia PI-103, or MK-2206 lethality following 6-24 h exposure ( Figure 1A ; lower panel), rapid and striking (e.g., 3 h) apoptosis was observed in cells in which both Bcl-2 and Bcl-xL were knocked down ( Figure 1A ; lower panel). Similar results were obtained with LY294002 (data not shown) and when cell growth and viability were monitored (Supplementary Figure 1B) .
These events were associated with pronounced Bax and Bak conformational changes (e.g., by PI-103; Figure 1B Figure 1C ), and apoptosis, reflected by caspase-3,-9, and PARP cleavage ( Figure 1D ). In contrast, agents exhibited minimal effects in the absence of doxycycline ( Figures 1A-D) . Notably, AKT was rapidly dephosphorylated/inactivated by PI3K/mTOR inhibitors (e.g., BEZ235 or PI-103) with or without doxycycline ( Figure 1D ). Conversely, inducible expression of DN-AKT or shAKT knockdown significantly increased whereas constitutively active AKT-DD significantly decreased ABT-737 lethality, reflected by caspase-3/PARP cleavage and Annexin V/PI positivity ( Supplementary Figures 2A-C) . Collectively, these findings indicate that the PI3K/AKT/mTOR pathway and Bcl-2/Bcl-xL interact coordinately to promote cell survival, suggesting that simultaneous targeting of these pathways may represent an effective antileukemic strategy.
PI3K/mTOR and Bcl-2/Bcl-xL inhibition in leukemia Dose response analysis of U937 cells revealed that while 0.5 μM ABT-737 was minimally toxic by itself, it substantially increased cell death induced by BEZ235 (e.g., 50-1000 nM; Figure 2A ) or PI-103 (e.g., 1-4 μM, Figure 2B ). Conversely, marginally toxic concentrations of BEZ235 (0.5 μM) or PI-103 (3 μM) sharply increased ABT-737 lethality (e.g., 0.25 -2 μM; Figure 2C ). Time course analysis of cells exposed simultaneously to BEZ235 (0.5 μM) and ABT-737 (0.5 μM) revealed approximately 20% cell death at 8 h, and substantially more pronounced lethality after 18 h (70 %, Supplementary Figure 3 Co-treatment with BEZ235 and ABT-737 sharply increases lethality and reduces colony formation of primary AML blasts while largely sparing normal CD34 + cells TUNEL assays of primary AML blasts revealed that simultaneous, but not individual, administration of BEZ235 and ABT-737 markedly increased apoptosis ( Figure 3A ), associated PI3K/mTOR and Bcl-2/Bcl-xL inhibition in leukemia discernible basal AKT phosphorylation/activation ( Figure 3E ). In contrast, non-responding specimens (#1 and #6), like normal CD34 + cells, displayed no detectable phospho-AKT ( Figure   3E ). Table 1 ).
Parallel colony-forming assays revealed that combined, but not individual, treatment with BEZ235 or LY294002 and ABT-737 strikingly reduced leukemic cell colony formation ( Figure 3F ). In contrast, the colony forming capacity of normal CD34 + cells was not significantly reduced by agents alone or in combination ( Figure 3G ). PI3K/mTOR and Bcl-2/Bcl-xL inhibition in leukemia survival (p < .01 versus single agent treatment; logrank test) whereas no effect was observed with ABT-737, and only a modest prolongation with BEZ235. Notably, mouse weights did not exhibit major changes (e.g., > 10%) in mice treated with agents alone or in combination (Supplementary Figure 7C) . Together, these findings indicate that combined treatment with BEZ235 and ABT-737 significantly inhibits tumor growth in vivo in association with diminished AKT phosphorylation, Mcl-1 down-regulation, apoptosis induction, and prolonged survival in leukemia-bearing mice.
Mcl
Research. The observation that tet-inducible dual knockdown of Bcl-2 and Bcl-xL sharply increases, whereas ectopic expression significantly diminishes PI3K inhibitor lethality indicate that these anti-apoptotic proteins play critical functional roles in protecting leukemic cells from lethality triggered by PI3K pathway interruption. Conversely, evidence that expression of tetresponsive dominant-negative or shRNA constructs against AKT substantially increase whereas constitutively active AKT decrease ABT-737 lethality argues that the PI3K/AKT pathway plays an important functional role in protecting leukemia cells from BH3 mimetic-induced cell death. 
